GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stratec SE (OTCPK:SBMDY) » Definitions » Forward PE Ratio

Stratec SE (Stratec SE) Forward PE Ratio : 0.00 (As of May. 26, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Stratec SE Forward PE Ratio?

Stratec SE's Forward PE Ratio for today is 0.00.

Stratec SE's PE Ratio without NRI for today is 44.85.

Stratec SE's PE Ratio for today is 44.85.


Stratec SE Forward PE Ratio Historical Data

The historical data trend for Stratec SE's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stratec SE Forward PE Ratio Chart

Stratec SE Annual Data
Trend
Forward PE Ratio

Stratec SE Quarterly Data
Forward PE Ratio

Competitive Comparison of Stratec SE's Forward PE Ratio

For the Medical Devices subindustry, Stratec SE's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stratec SE's Forward PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Stratec SE's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Stratec SE's Forward PE Ratio falls into.



Stratec SE Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Stratec SE  (OTCPK:SBMDY) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Stratec SE Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Stratec SE's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Stratec SE (Stratec SE) Business Description

Traded in Other Exchanges
Address
Gewerbestrasse 37, Birkenfeld, RP, DEU, 75217
Stratec SE designs and manufactures automated analyzer systems for laboratory data management and solutions for molecular diagnostic sample preparation and stabilization. Its business segments are Instrumentation, Diatron and Smart Consumables. Its Instrumentation segment is engaged in designing and manufacturing automated analyzer systems for clinical diagnostics and biotechnology customers. The Diatron segment comprises the business with systems, system components, consumables, and tests in the low throughput hematology and clinical chemistry segment. Its Smart Consumables segment is engaged in developing and selling scientific materials, such as nucleic acid purification. The company generates maximum revenue from the Instrumentation segment.

Stratec SE (Stratec SE) Headlines

From GuruFocus